Pharmaceuticals IG symposium2018-05-07T12:12:38+00:00

Human Health Risk Assessment of antibiotic resistance development in the environment – State of the science 6 years after the Quebec workshop

Sunday 13 May, 1:00 p.m. – 5:30 p.m., Session Room O

Gerd Maack, German Environment Agency (UBA), Germany

Thomas Backhaus, University of Gothenburg, Sweden

Jason Snape, Astra Zeneca, UK

The workshop held 4 – 8 March 2012 in Québec, Canada, aimed to define the scope and objectives of an environmental assessment of antibiotic-resistance risks to human health. Research needs were identified to enable human health risk assessments (HHRA) that focus on the role of the environment in the failure of antibiotics to treat antibiotic-resistant bacteria (ARB). The participants proposed that environmental aspects of antibiotic-resistance development be included in the processes of any HHRA addressing ARB. Because of limited available data, a multi-criteria decision analysis approach would be a useful way to undertake an HHRA of environmental antibiotic resistance that informs risk managers.

Since then, a number of scientific studies have identified the potential negative impacts of ARB and antimicrobials on the environment. This is also explicitly emphasized in the EU-Commission “European One Health Action Plan against antimicrobial resistance (AMR)”. This publication highlights the growing concern of the development and spread of AMR in the environment.

The aim of this symposium is to inform about the state of the art after 6 years after the Québec workshop from different views. So the overall antibiotic use is higher in food-producing animals than in humans, but the situation varies across countries and according to the antibiotics. This will be highlighted in the first presentation, including the use of human second line antibiotics for standard treatment in animals. The second presentation will focus on a so far neglected entry path into the environment, namely the production sites of pharmaceuticals and their global significance. The third keynote will highlight the industry effort to tackle this problem.

Programme (13:00 – 17:30, health break at 14:45)

Keynote presentations…

…Followed by Panel Discussion.

Participation costs 65€. You can register in combination with conference registration.


For any questions, feel free to contact Gerd Maack or Roel Evens (scientific programme), or Veerle Vandeveire (meeting registration).